Navigation Links
Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
Date:9/3/2008

ies," said Edward Lanphier, Sangamo's president and CEO. "VEGF has been demonstrated to have a fundamental role in the growth and health of blood vessels, nerves and muscle and we believe that our approach of using a ZFP TF to stimulate the expression of all of the natural forms of a subject's own VEGF-A gene may have potential therapeutic benefit for a variety of neurodegenerative conditions including ALS."

About the Study, SB-509-801

A total of 40 subjects with ALS will be enrolled in this trial and randomized into one of two treatment cohorts. The first cohort of 35 subjects will receive 60 mg of SB-509 in a divided dose into muscles in the arm, leg, and along the spine on both sides of the body. A second cohort of 5 subjects will receive 60 mg of SB-509 in a divided dose into the muscles in the lower limb in both legs. Each subject will receive a total of two treatments of 60 mg of SB-509 intramuscularly three months apart on Day 0 and Day 90. The study will be carried out over 11 months, including 2 months for screening, 3 months for two study treatments, and 6 months of follow-up after administration of the final dose. Individuals interested in participating in this trial should visit http://www.clinicaltrials.gov/ or http://www.alsa.org

About Amyotrophic Lateral Sclerosis (ALS)

More than 30,000 Americans have ALS, according to the ALS Association, a nonprofit organization that supports ALS research and public and patient education about the disease. 3,000 to 5,000 new cases of the disease are diagnosed every year. Men and women of all ethnic and racial groups are equally affected, usually between the ages of 40 and 70. The disease attacks the motor nerves, nerve cells in the brain and spinal cord that control the body's voluntary muscles. As the motor nerves begin to die, the muscles weaken and shrink. Early symptoms of ALS ma
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
2. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
3. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
4. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
5. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
6. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
7. Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
8. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
9. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
10. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
11. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... -- Reproductive Medicine Associates of New York ... nationally and internationally-recognized leader in providing exceptional quality and ... to announce a new collaboration with EMD Serono and ... the sacrifices made by veterans and their families for ... allow qualifying veterans and the spouses of veterans to ...
(Date:7/22/2014)... July 22, 2014 WuXi PharmaTech (Cayman) Inc. (NYSE: ... device R&D outsourcing company with operations in China ... today announced that it will release financial results for the ... closes on Wednesday, August 13, 2014 (which will be Thursday ... be available on the investor relations section of the Company,s ...
(Date:7/22/2014)... SOUTH EASTON, Mass. , July 22, ... ("PBI" or the "Company") and Parabase Genomics ... have entered into a strategic research and ... of the collaboration, PBI will develop a ... neonatal molecular diagnostics and newborn confirmatory testing ...
Breaking Medicine Technology:Reproductive Medicine Associates of New York Collaborates with EMD Serono to Offer Treatment Assistance to Eligible Veterans and their Spouses 2Reproductive Medicine Associates of New York Collaborates with EMD Serono to Offer Treatment Assistance to Eligible Veterans and their Spouses 3WuXi PharmaTech Schedules Second-Quarter 2014 Earnings Release 2Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 2Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 3Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 4
... May 30, 2011 Reportlinker.com announces ... is available in its catalogue: ... – A key risk factor for ... http://www.reportlinker.com/p0536561/Epidemiology-Major-Abdominal-Surgery-–-A-key-risk-factor-for-deep-vein-thrombosis-and-pulmonary-embolism.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=NoCategory ...
... 2011 Reportlinker.com announces that a new ... catalogue: The Global Pharmaceutical ... http://www.reportlinker.com/p0535967/The-Global-Pharmaceutical-Fine-Chemicals-Market-Outlook-to-2015.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Chemical_and_Material ... provides a comprehensive overview of the global ...
Cached Medicine Technology:Reportlinker Adds Epidemiology: Major Abdominal Surgery - A key risk factor for deep vein thrombosis and pulmonary embolism 2Reportlinker Adds The Global Pharmaceutical Fine Chemicals Market Outlook to 2015 2Reportlinker Adds The Global Pharmaceutical Fine Chemicals Market Outlook to 2015 3Reportlinker Adds The Global Pharmaceutical Fine Chemicals Market Outlook to 2015 4Reportlinker Adds The Global Pharmaceutical Fine Chemicals Market Outlook to 2015 5Reportlinker Adds The Global Pharmaceutical Fine Chemicals Market Outlook to 2015 6
(Date:7/22/2014)... undergoing a minimally invasive hysterectomy using electric power morcellation, ... at the time of the procedure, according to a ... concern that this procedure, in which the uterus is ... of undetected malignancies. , Despite the commercial availability of ... the prevalence of malignancy at the time of electric ...
(Date:7/22/2014)... of Hematology (ASH) will present the Society,s highest honor, ... in Hematology, to Kanti R. Rai, MD, of the ... for his 50-year career combining landmark clinical leukemia research, ... care. , The Wallace H. Coulter Award for ... who has been a vital contributor to the field ...
(Date:7/22/2014)... mechanisms with cancer, according to a new report by ... , published in PLOS ONE on July ... very same inhibitors of apoptosis, or cell destruction, in ... diseases. Henry Kaminski, M.D. , chair of the ... and Health Sciences (SMHS), as well as colleagues from ...
(Date:7/22/2014)... Ticket Down is a reliable source ... Fedex Field in Landover, MD. There has never been a ... international soccer. After the success of the American national soccer team ... and well. One way that fans of the world’s sport will ... the 2014 Guinness International Champions Cup. The tournament will kick off ...
(Date:7/22/2014)... The market for botulinum neurotoxin (BoNT) products has ... novel medical indications created and due to more cosmetic ... physical appearance is extremely valued. Although the BoNT market ... companies and technologies are setting ground for biosuperiors and ... price of 1st-gen products under pressure, only innovation is ...
Breaking Medicine News(10 mins):Health News:Study examines presence of uterine cancers at the time of hysterectomy using morcellation 2Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 2Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 3Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 4Health News:New research finds pathogenic connection between autoimmune disorders and cancer 2Health News:Manchester United vs. Inter Milan Tickets Fedex Field Landover: Ticket Down Slashes Ticket Prices for Inter Milan ManU International Champions Cup Match in Washington, DC 2Health News:Manchester United vs. Inter Milan Tickets Fedex Field Landover: Ticket Down Slashes Ticket Prices for Inter Milan ManU International Champions Cup Match in Washington, DC 3Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 2Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 3Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 4
... April 24 Actavis Group, the,international generic pharmaceuticals ... a case study on the Company and its ... Actavis, ,Winning,formula," was presented in an MBA class ... will be made available to business,schools around the ...
... Was Served, -, LOS ANGELES, April 23 ... against Yolanda McGriff, a Los Angeles-,based healthcare worker who ... a low-income, disabled veteran. McGriff was arrested for,trespass-related violations ... employer, a man who lived in what used to ...
... Reflecting the growing concern,over health care costs and ... afford a comfortable retirement decreased over the past ... of the Retirement Confidence Survey(R),(RCS), according to just-released ... News Release, go to:, http://www.prnewswire.com/mnr/ebri/32335/ , The ...
... of image-guided ... therapy, PALO ALTO, Calif., April 23 Varian Medical,Systems ... than 60 orders for,its new RapidArc radiotherapy product for faster ... but have also come in from Europe and Asia,since the ...
... the voice of the,public, Hero Nutritionals, Inc. is launching ... adults. Hero Nutritionals, manufacturer of Yummi,Bears, the original gummy ... moms buying Yummi Bears, for an adult version of ... Yummi Bears is the,nation,s #1 & best tasting gummy ...
... using a bionic boot found that during walking, the ankle ... of energy compared to isolated muscles---in other words, the spring ... efficiently. , While much has been done measuring the efficiency ... measure the energy efficiency of a body part such as ...
Cached Medicine News:Health News:Harvard Business School Publishes a Case Study on Robert Wessman and Actavis 2Health News:Harvard Business School Publishes a Case Study on Robert Wessman and Actavis 3Health News:Case Dropped Against Healthcare Worker Who Was Arrested While Providing Care to an Elderly, Disabled Man in Los Angeles Home 2Health News:Video: 18th Annual Retirement Confidence Survey(R): Health Care, Economy Major Concerns in Workers' Record Drop in Retirement Confidence 2Health News:Video: 18th Annual Retirement Confidence Survey(R): Health Care, Economy Major Concerns in Workers' Record Drop in Retirement Confidence 3Health News:Video: 18th Annual Retirement Confidence Survey(R): Health Care, Economy Major Concerns in Workers' Record Drop in Retirement Confidence 4Health News:Varian Medical Systems Announces Record Demand for New RapidArc(TM) Radiotherapy Treatment Capability 2Health News:Varian Medical Systems Announces Record Demand for New RapidArc(TM) Radiotherapy Treatment Capability 3Health News:Varian Medical Systems Announces Record Demand for New RapidArc(TM) Radiotherapy Treatment Capability 4Health News:Varian Medical Systems Announces Record Demand for New RapidArc(TM) Radiotherapy Treatment Capability 5Health News:Hero Nutritionals Introduces a New Adult Vitamin for the Taste Buds 2Health News:The spring in your step is more than just a good mood 2
CVC 9005 Hematocrit Calibration Verification Controls are materials used for verifying the calibration and linearity of hematocrit sensors in IRMA TRUpoint cartridges for systems using software versi...
... quality control material used for monitoring the performance ... is for specific use on Bayer analyzers that ... and 270) and the AVOX Systems CO-Oximeters (4000 ... on the IRMA TRUpoint®. CC 527 is available ...
RNA1c Control is an assayed quality control material used for monitoring the performance of Bayer DCA Analyzers that measure Hemoglobin A1c. It may be used on DCA 2000 and 2000+ analyzers....
... offering an innovative way to capture and ... more than just a revolutionary advancement. The ... the worlds first Convertible Ultrasound system, instantly ... a premium compact, ultrasound system with all ...
Medicine Products: